EECP For Physicians
EECP® (Enhanced External Counterpulsation) therapy is for patients suffering from angina pectoris and other
cardiovascular-related diseases. At West Los Angeles EECP Center and Inglewood Los Angeles EECP Center we work directly with patients’ physicians. EECP is for everyone with a heart, and patients need their managing physicians to understand the efficacy of EECP therapy in heart disease treatment.
About Los Angeles EECP Centers
At Los Angeles EECP Centers, the leading EECP therapy is delivered. Since 2002, Sara Soulati has worked alongside physician practices to create the largest, outpatient, stand-alone centers that feature the Sara Soulati EECP Method. This protocol is safe, non-invasive and medication free. In addition to the FDA cleared technology called Enhanced External Counterpulsation, the Sara Soulati EECP Method combines the Sara Soulati Health for Life Program. This lifestyle modification program prevents and reverses disease.
There are more than 900 academic institutions and independent physician practices throughout the world that use EECP therapy for cardiovascular disease. They include:
- Mayo Clinic
- St. Francis Heart Hospital
- Beth Israel Medical Center
- University of New York at Stony Brook
- The Cleveland Clinic
- NYU-Langone Medical Center
- University of California Los Angeles
- University of California San Diego
- Duke University Medical Center
- University of Pittsburgh Medical Center
About External Counterpulsation Treatment
EECP therapy is non-surgical, requires no medication and is an FDA-cleared treatment for cardiovascular disease.
- The device was invented in the late 1950s at Harvard University.
- In the 1970s, the therapy was in use for acute myocardial infarction and cardiogenic shock.
The U.S. Food and Drug Administration cleared EECP in:
- 1995 for chronic stable and unstable angina pectoris, cardiogenic shock and acute myocardial infarction.
- 2002 for congestive heart failure
- In 2016, it removed clearance for cardiogenic shock and congestive heart failure
Mechanism of EECP
EECP promotes angiogenesis, growth of new collaterals to improve circulation. It increases nitric oxide, vascular endothelial growth factor and other endothelial growth factors.
- The squeezing mechanism of counterpulsation improves the hemodynamics of blood flow and shear stress to help generate progenitor and hematopoietic stem cells in the bone marrow improving endothelial function and reprofusing organ tissue.
- In addition, elevated levels of nitric oxide and vascular endothelial growth factor are evident during the treatment that helps improve circulation as well as stimulates angiogenesis, resulting in improved endothelial function and a reduction of both circulating inflammatory markers and arterial stiffness.
The mechanism of counterpulsation includes:
- Increased venous return
- Increased preload/stretch
- Increased cardiac output
- Retrograde arterial flow
- Increased diastolic pressure
- Increased intracoronary perfusion
- Increased vascular recoil and systolic unloading
- Decreased systemic vascular resistance
- Decreased afterload
EECP, Angina Pectoris & Disease
The Centers for Medicare and Medicaid Services (CMS) and other third-party insurance payers have been reimbursing treatment of angina symptoms with EECP since 1999. The history of EECP can be found here.
EECP is proven to help patients with the following angina symptoms:
- Ischemic heart disease with associated symptoms of fatigue
- Angina pectoris and unspecified angina pectoris
- Heart failure occurring with less than ordinary exertion and chronic stable angina pectoris
Cardiovascular Disease Patients For EECP
Patients with any of the following symptoms, pre-existing or current conditions may be candidates for EECP therapy:
- Inoperable patients
- Excessive risk or comorbid conditions for invasive procedures
- Refusal/unwillingness for invasive procedures
- Inadequate relief from medication
- Post-invasive patients with previous CABG or PCI within 5+ years
- Diabetic with underlying ischemic heart disease (have neuropathy, shortness of breath)
- Inactive or sedentary lifestyle (fatigue, palpitation, shortness of breath, atypical pain, chest pain)
- Small vessel or diffuse disease
- Cardiac Syndrome X
- Mild refractory angina pectoris (CCS Class II)
- Significant silent ischemia
- Left main disease
- Systolic or diastolic heart failure
- Severe, diffuse coronary atherosclerosis
Although the patient benefits of this therapy have been proven to last for more than five years, it is not uncommon for Medicare or other third-party payers to reimburse for repeat treatment sessions (35 days) twice annually.
Clinical studies have shown there is a definite trend demonstrating EECP therapy, when done post PCI, may reduce restenosis rates.
- Sustainable increase in coronary perfusion
- Retrograde arterial flow (shear stress) increases endothelial function
- Peripheral training effects (similar to exercise)
- Cardiac remodeling (stunned and hibernated myocardium)
- Improvement in oxygen consumption
- Regression of atherosclerosis
- Improvement in ventricular function
- Increase in cardiac output
- Decrease in cardiac workload of the heart
- Release of growth factors
- Increased coronary pressure
- Increased levels of nitric oxide and decreased levels ANP and BNP
- Acute improvement in peripheral endothelial function (increase in RH-PAT index)
- Increased time to the onset of ischemia
- Decrease in number and severity of angina episodes
- Reduction in angina and heart failure classifications
- Decreased medication (nitroglycerin and ranexa)
A thorough list of Patient Benefits of EECP Therapy Proven in Clinical Studies is available in our EECP For Physicians Brochure. Please complete our Contact Us form, and we will email you a copy.
Sara Soulati is CEO/Founder of Global Cardio Care® Inc.
Global Cardio Care is the leader in developing EECP centers with physicians. Global Cardio Care launched in 2002 and developed the largest out-patient, stand-alone center for EECP therapy. At each of two centers, West Los Angeles EECP Center and Inglewood EECP Center, Sara Soulati Health for Life Program is offered exclusively. This program with EECP provides patients with the opportunity to experience a non-invasive and medication-free therapy.
About Sara Soulati
In 1996, Sara Soulati launched her career in the field of EECP. She is one of the earliest pioneers in the delivery of the treatment. She has been managing physician practices since the late 1990s. She is founder and CEO of Global Cardio Care®, the team that manages the out-patient stand-alone centers delivering EECP therapy.
The Sara Soulati Health For Life Program features The Sara Soulati Method of EECP, a lifestyle modification program and total approach to disease prevention and treatment.